RLAY Relay Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLAY

Price (delayed)

$6.155

Market cap

$807.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.79

Enterprise value

$714.43M

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
RLAY's quick ratio has soared by 58% year-on-year and by 55% since the previous quarter
The debt has contracted by 7% YoY and by 2.1% from the previous quarter
The equity has declined by 21% year-on-year and by 3.4% since the previous quarter
Relay Therapeutics's net income has decreased by 18% YoY and by 4.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://relaytx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RLAY
Market
Shares outstanding
131.18M
Market cap
$807.41M
Enterprise value
$714.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
29.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.97
Earnings
Revenue
$25.55M
EBIT
-$341.97M
EBITDA
-$336.7M
Free cash flow
-$304.44M
Per share
EPS
-$2.79
Free cash flow per share
-$2.48
Book value per share
$6.1
Revenue per share
$0.21
TBVPS
$6.87
Balance sheet
Total assets
$843.98M
Total liabilities
$91.98M
Debt
$53.47M
Equity
$752M
Working capital
$739.83M
Liquidity
Debt to equity
0.07
Current ratio
25.44
Quick ratio
24.87
Net debt/EBITDA
0.28
Margins
EBITDA margin
-1,318%
Gross margin
100%
Net margin
-1,338.7%
Operating margin
-1,485.3%
Efficiency
Return on assets
-36.5%
Return on equity
-42.4%
Return on invested capital
-43.8%
Return on capital employed
-42%
Return on sales
-1,338.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
-3.07%
1 week
0.74%
1 month
-18.26%
1 year
-47.75%
YTD
-44.1%
QTD
-25.84%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$25.55M
Gross profit
$25.55M
Operating income
-$379.42M
Net income
-$341.97M
Gross margin
100%
Net margin
-1,338.7%
The net margin has soared by 94% YoY but it has contracted by 6% from the previous quarter
Relay Therapeutics's operating margin has soared by 93% YoY but it has decreased by 4% from the previous quarter
RLAY's operating income is down by 22% year-on-year and by 2.9% since the previous quarter
Relay Therapeutics's net income has decreased by 18% YoY and by 4.9% QoQ

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
1.01
P/S
29.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.97
The EPS has declined by 8% year-on-year and by 4.1% since the previous quarter
The P/B is 44% lower than the last 4 quarters average of 1.8
The equity has declined by 21% year-on-year and by 3.4% since the previous quarter
The stock's price to sales (P/S) is 97% less than its last 4 quarters average of 849.3

Efficiency

How efficient is Relay Therapeutics business performance
The return on sales has surged by 94% year-on-year but it has declined by 6% since the previous quarter
The company's return on equity fell by 30% YoY and by 11% QoQ
The ROA is down by 29% YoY and by 12% QoQ
The return on invested capital has declined by 24% year-on-year and by 12% since the previous quarter

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
RLAY's current ratio has soared by 59% year-on-year and by 55% since the previous quarter
RLAY's quick ratio has soared by 58% year-on-year and by 55% since the previous quarter
The debt is 93% less than the equity
The equity has declined by 21% year-on-year and by 3.4% since the previous quarter
Relay Therapeutics's debt to equity has increased by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.